Urogen Pharma $URGN Shares Sold by ARK Investment Management LLC

ARK Investment Management LLC trimmed its holdings in shares of Urogen Pharma (NASDAQ:URGN) by 23.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 126,720 shares of the company’s stock after selling 39,374 shares during the period. ARK Investment Management LLC owned about 0.27% of Urogen Pharma worth $2,528,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. State of Wyoming purchased a new position in Urogen Pharma in the third quarter worth $66,000. Osaic Holdings Inc. lifted its holdings in Urogen Pharma by 491.2% in the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after purchasing an additional 3,070 shares in the last quarter. Strs Ohio acquired a new position in Urogen Pharma in the third quarter valued at $76,000. CWM LLC lifted its position in Urogen Pharma by 18.0% during the third quarter. CWM LLC now owns 4,271 shares of the company’s stock worth $85,000 after buying an additional 650 shares during the period. Finally, Tower Research Capital LLC TRC boosted its stake in Urogen Pharma by 422.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock worth $94,000 after buying an additional 5,571 shares during the last quarter. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

Urogen Pharma News Summary

Here are the key news stories impacting Urogen Pharma this week:

• Positive Sentiment: Urogen’s quarterly report beat EPS expectations (smaller loss than forecast), prompting an early gap‑up in the shares as investors cheered the outcome. Read More.
• Positive Sentiment: D. Boral Capital assigned a “Buy” rating to URGN, which supports demand from investors looking for upside in the drug’s commercial rollout and can help short‑term sentiment. Read More.
• Neutral Sentiment: Coverage discusses UroGen weighing the commercial success of ENVISION and an expanded loan to support its bladder cancer push — this could fund growth but also increases leverage and execution risk, so the market reaction is ambiguous. Read More.
• Negative Sentiment: HC Wainwright substantially lowered near‑term EPS estimates: Q2 2026 to ($0.64) from ($0.42), Q3 2026 to ($0.42) from ($0.14), Q4 2026 to ($0.33) from $0.01, and cut FY2026 to ($1.99) from ($1.18). (They did slightly raise Q1 2026 to ($0.60) from ($0.63) and project FY2027 at $0.45.) These deeper downgrades to 2026 earnings signal weaker near‑term profitability expectations and are the main negative catalyst weighing on the stock. Read More.

Urogen Pharma Trading Down 2.7%

Urogen Pharma stock opened at $19.61 on Friday. Urogen Pharma has a 1-year low of $3.42 and a 1-year high of $30.00. The firm’s fifty day simple moving average is $20.94 and its 200-day simple moving average is $20.86. The company has a market capitalization of $954.61 million, a P/E ratio of -6.13 and a beta of 1.34.

Urogen Pharma (NASDAQ:URGN) last posted its earnings results on Monday, March 2nd. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.12. The business had revenue of $37.84 million for the quarter, compared to analyst estimates of $39.92 million. On average, equities research analysts predict that Urogen Pharma will post -3.12 earnings per share for the current year.

Insider Activity at Urogen Pharma

In related news, General Counsel Jason Drew Smith sold 7,479 shares of the firm’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total value of $147,261.51. Following the completion of the transaction, the general counsel directly owned 51,326 shares of the company’s stock, valued at $1,010,608.94. This trade represents a 12.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mark Schoenberg sold 7,373 shares of Urogen Pharma stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total value of $145,174.37. Following the sale, the insider directly owned 144,985 shares in the company, valued at $2,854,754.65. The trade was a 4.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 4.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Wall Street Zen upgraded Urogen Pharma from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. D. Boral Capital reiterated a “buy” rating and set a $33.00 price objective on shares of Urogen Pharma in a research note on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday, January 21st. Finally, Oppenheimer reiterated an “outperform” rating on shares of Urogen Pharma in a report on Monday. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $33.29.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.